NUVB
Price
$3.20
Change
+$0.19 (+6.31%)
Updated
Sep 26, 04:59 PM (EDT)
Capitalization
1.03B
40 days until earnings call
RCUS
Price
$12.85
Change
+$0.48 (+3.88%)
Updated
Sep 26, 04:59 PM (EDT)
Capitalization
1.37B
46 days until earnings call
Interact to see
Advertisement

NUVB vs RCUS

Header iconNUVB vs RCUS Comparison
Open Charts NUVB vs RCUSBanner chart's image
Nuvation Bio
Price$3.20
Change+$0.19 (+6.31%)
Volume$24.77K
Capitalization1.03B
Arcus Biosciences
Price$12.85
Change+$0.48 (+3.88%)
Volume$7.44K
Capitalization1.37B
NUVB vs RCUS Comparison Chart in %
Loading...
NUVB
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
RCUS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
NUVB vs. RCUS commentary
Sep 27, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is NUVB is a Buy and RCUS is a Buy.

Interact to see
Advertisement
COMPARISON
Comparison
Sep 27, 2025
Stock price -- (NUVB: $3.20 vs. RCUS: $12.85)
Brand notoriety: NUVB and RCUS are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: NUVB: 42% vs. RCUS: 20%
Market capitalization -- NUVB: $1.03B vs. RCUS: $1.37B
NUVB [@Biotechnology] is valued at $1.03B. RCUS’s [@Biotechnology] market capitalization is $1.37B. The market cap for tickers in the [@Biotechnology] industry ranges from $97.91B to $0. The average market capitalization across the [@Biotechnology] industry is $1.89B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

NUVB’s FA Score shows that 0 FA rating(s) are green whileRCUS’s FA Score has 0 green FA rating(s).

  • NUVB’s FA Score: 0 green, 5 red.
  • RCUS’s FA Score: 0 green, 5 red.
According to our system of comparison, both NUVB and RCUS are a bad buy in the long-term.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

NUVB’s TA Score shows that 5 TA indicator(s) are bullish while RCUS’s TA Score has 2 bullish TA indicator(s).

  • NUVB’s TA Score: 5 bullish, 4 bearish.
  • RCUS’s TA Score: 2 bullish, 4 bearish.
According to our system of comparison, NUVB is a better buy in the short-term than RCUS.

Price Growth

NUVB (@Biotechnology) experienced а -0.62% price change this week, while RCUS (@Biotechnology) price change was +3.71% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +4.14%. For the same industry, the average monthly price growth was +9.25%, and the average quarterly price growth was +54.64%.

Reported Earning Dates

NUVB is expected to report earnings on Nov 05, 2025.

RCUS is expected to report earnings on Nov 11, 2025.

Industries' Descriptions

@Biotechnology (+4.14% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
RCUS($1.37B) has a higher market cap than NUVB($1.03B). NUVB YTD gains are higher at: 20.301 vs. RCUS (-13.700). NUVB has higher annual earnings (EBITDA): -201.17M vs. RCUS (-282M). RCUS has more cash in the bank: 911M vs. NUVB (608M). NUVB has less debt than RCUS: NUVB (57.8M) vs RCUS (109M). RCUS has higher revenues than NUVB: RCUS (262M) vs NUVB (14.4M).
NUVBRCUSNUVB / RCUS
Capitalization1.03B1.37B75%
EBITDA-201.17M-282M71%
Gain YTD20.301-13.700-148%
P/E RatioN/AN/A-
Revenue14.4M262M5%
Total Cash608M911M67%
Total Debt57.8M109M53%
FUNDAMENTALS RATINGS
RCUS: Fundamental Ratings
RCUS
OUTLOOK RATING
1..100
11
VALUATION
overvalued / fair valued / undervalued
1..100
49
Fair valued
PROFIT vs RISK RATING
1..100
100
SMR RATING
1..100
98
PRICE GROWTH RATING
1..100
40
P/E GROWTH RATING
1..100
98
SEASONALITY SCORE
1..100
50

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

TECHNICAL ANALYSIS
Technical Analysis
NUVBRCUS
RSI
ODDS (%)
Bearish Trend 2 days ago
76%
Bearish Trend 2 days ago
90%
Stochastic
ODDS (%)
Bullish Trend 2 days ago
83%
Bearish Trend 2 days ago
85%
Momentum
ODDS (%)
Bearish Trend 2 days ago
86%
N/A
MACD
ODDS (%)
Bearish Trend 2 days ago
76%
N/A
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
82%
Bearish Trend 2 days ago
80%
TrendMonth
ODDS (%)
Bullish Trend 2 days ago
82%
Bullish Trend 2 days ago
77%
Advances
ODDS (%)
Bullish Trend 5 days ago
80%
Bullish Trend 9 days ago
82%
Declines
ODDS (%)
Bearish Trend 9 days ago
84%
Bearish Trend 18 days ago
81%
BollingerBands
ODDS (%)
Bullish Trend 2 days ago
76%
Bearish Trend 2 days ago
82%
Aroon
ODDS (%)
Bullish Trend 2 days ago
80%
Bullish Trend 2 days ago
79%
View a ticker or compare two or three
Interact to see
Advertisement
NUVB
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
RCUS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
VCSAX104.82N/A
N/A
Vanguard Consumer Staples Index Admiral
EIDIX18.51N/A
N/A
Eaton Vance Global Equity Income I
SAOAX30.57N/A
N/A
NAA Opportunity A
MNDJX29.75N/A
N/A
MFS New Discovery R4
SPEDX22.34N/A
N/A
Alger Dynamic Opportunities A

NUVB and

Correlation & Price change

A.I.dvisor indicates that over the last year, NUVB has been loosely correlated with BEAM. These tickers have moved in lockstep 48% of the time. This A.I.-generated data suggests there is some statistical probability that if NUVB jumps, then BEAM could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To NUVB
1D Price
Change %
NUVB100%
+6.31%
BEAM - NUVB
48%
Loosely correlated
-0.48%
DNLI - NUVB
47%
Loosely correlated
+3.87%
RCUS - NUVB
46%
Loosely correlated
+3.88%
XNCR - NUVB
45%
Loosely correlated
+12.00%
OCUL - NUVB
44%
Loosely correlated
+2.33%
More